Clinical trials will advance treatment of COVID-19 infection. September 11, 2023, Beijing, China - Sinovac Biotech Ltd. , a leading provider of biopharmaceutical products in.
Sinovac Biotech Ltd. SINOVAC or the Company NASDAQ SVA a leading provider of biopharmaceutical products in China announced that the Company has completed the phase I clinical trial for its broadspectrum neutralizing antibody product the AntiCOVID19 Antibody SA55 Injection SA55 Injection in Beijing and has entered the phase II clinical trial in Shanghai after successfully enrolling its first participant recently.